Evidence map›Paper›PMID 42007147›Full record

ArticleAmerican journal of translational research2026

Gypenosides attenuate H

Chao Ma, Kaijun Li, Haoyu Li, Xinmin Li, Wei Liu, Xian Li, Jinyuan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chao MaDepartment of Ophthalmology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
Kaijun LiDepartment of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Haoyu LiDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Xinmin LiDepartment of Ophthalmology, The First Affiliated Hospital of Xinxiang Medical University Xinxiang 453100, Henan, China.
Wei LiuDepartment of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Xian LiFaculty of Biology, University of Manchester Manchester M13 9PL, England, United Kingdom.
Jinyuan ChenDepartment of Ophthalmology, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the antioxidative effects of gypenosides (Gyps) in orbital fibroblasts (OFs) derived from patients with thyroid-associated ophthalmopathy (TAO) and to validate their therapeutic efficacy

methodsBioinformatics analyses were performed to screen potential genes and signalling pathways underlying the effect of Gyps in OFs. OFs were isolated from orbital connective tissues of both TAO patients and non-TAO controls. CCK-8 assay was used to detect cell proliferation. Oxidative stress was evaluated by measuring reactive oxygen species (ROS) and superoxide dismutase (SOD) levels. Quantitative reverse transcriptive-polymerase chain reaction (RT-qPCR), ELISA, and western blotting were employed to ascertain the effects of Gyps on H

resultsBioinformatic analysis revealed that the identified genes were primarily enriched in metabolic and oxidative stress-related pathways.

conclusionsGyps exert significant antioxidative, anti-inflammatory, and anti-fibrotic effects by activating the Nrf2/ERK/HO-1 signalling pathway in both

Indexed as

animal modelsbioinformaticsGypenosidesorbital fibroblastoxidative stressthyroid-associated ophthalmopathy

Identifiers

PMID42007147
PMCPMC13090864

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.